文献速递神经肿瘤

MEDI-575(抗血小板衍生生长因子α抗体)治疗复发性胶质母细胞瘤的II期研究

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
PubMed 文献 · J Neurooncol · 2016-11-14

这项多中心、单臂、开放标签II期研究评估了MEDI-575在复发性胶质母细胞瘤患者中的疗效与安全性。56例患者接受MEDI-575 25 mg/kg静脉输注每21天一次,6个月无进展生存率为15.4%(90%CI 8.1-24.9),中位总生存期9.7个月(90%CI 6.5-11.8),未观察到完全或部分缓解。MEDI-575耐受性良好但临床活性有限。

要点

  • 6个月无进展生存率为15.4%(90%CI 8.1-24.9),中位无进展生存期1.4个月(90%CI 1.4-1.8)。
  • 中位总生存期为9.7个月(90%CI 6.5-11.8),无完全或部分缓解,23例(41.1%)最佳疗效为疾病稳定。
  • 最常见治疗相关不良事件为腹泻(16%)、恶心(13%)和乏力(13%),12例(21%)报告≥3级不良事件。

核心结论

  • MEDI-575耐受性良好,但在复发性胶质母细胞瘤中临床活性有限。

研究设计与样本

  • 多中心、单臂、开放标签II期研究,纳入56例首次复发的胶质母细胞瘤成人患者,接受MEDI-575 25 mg/kg静脉输注60分钟,每21天一次,直至疾病进展或不可耐受毒性。

主要发现

  • 6个月无进展生存率为15.4%(90%CI 8.1-24.9)。
  • 中位无进展生存期1.4个月(90%CI 1.4-1.8),中位总生存期9.7个月(90%CI 6.5-11.8)。
  • 无完全或部分缓解,23例(41.1%)最佳疗效为疾病稳定。
  • 最常见治疗相关不良事件为腹泻(16%)、恶心(13%)和乏力(13%);12例(21%)报告≥3级不良事件,其中脑积水(3例)、吞咽困难(2例)和惊厥(2例)在超过1例患者中报告;2例发生治疗相关≥3级不良事件(淋巴细胞计数降低和乏力各1例);7例(13%)因不良事件终止MEDI-575。
  • 胶质母细胞瘤细胞和肿瘤相关间质细胞中PDGFRα标记高度可变,与无进展生存期无相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-α expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23-79), 66 % were male, and 66 % were aged ≥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1-24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ≥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ≥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Phuphanich S, Raizer J, Chamberlain M, et al. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma. J Neurooncol. 2016. PMID: 27844311. doi:10.1007/s11060-016-2287-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。